Can MAPKs Be Targets for Toxicological Interventions?
Yes, targeting MAPKs represents a promising strategy for toxicological interventions. Inhibitors of specific MAPK pathways can mitigate adverse effects caused by toxicants. For example, p38 inhibitors are being explored for their potential to reduce inflammation and tissue damage. However, given the complexity and redundancy of MAPK signaling, therapeutic interventions must be precisely tailored to avoid off-target effects and preserve physiological functions.
